^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    SLC28A3 expression and fludarabine-emergent autoimmune hemolytic anemia in chronic lymphocytic leukemia: A new player in an old equation. (PubMed, Biomol Biomed)
    This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.
    Journal
    |
    SLC28A3 (Solute Carrier Family 28 Member 3)
    |
    cyclophosphamide • fludarabine IV
    1d
    Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov)
    P1, N=20, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2026 --> Nov 2025
    Enrollment open • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cyclophosphamide • Nailike (olverembatinib) • fludarabine IV • ThisCART19A
    2d
    Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    3d
    18-C-0125: T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV
    3d
    A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=3, Terminated, Nanjing Legend Biotech Co. | N=42 --> 3 | Trial completion date: Apr 2030 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Apr 2028 --> Mar 2026; pipeline adjustment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    3d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Initiation date: May 2026 --> Aug 2026
    Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • zolacabtagene autoleucel (BMS-986353)
    4d
    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (clinicaltrials.gov)
    P1/2, N=124, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2030 | Trial primary completion date: Jan 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    7d
    Identifying Ultra-High Risk Large B-Cell Lymphoma Patients for Early Treatment with Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY Study (ACTRN12625000673448)
    P2, N=120, Recruiting, Australasian Leukaemia and Lymphoma Group | Not yet recruiting --> Recruiting | N=24 --> 120
    Enrollment open • Enrollment change • Trial initiation date
    |
    CD19 positive
    |
    cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    7d
    M-2024-423: US Zamto-cel Autoimmune Diseases (clinicaltrials.gov)
    P1, N=48, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • zamtocabtagene autoleucel (MB-CART2019.1)
    7d
    IOV-GM1-201: A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Iovance Biotherapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2029 | Trial primary completion date: Jun 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    cyclophosphamide • fludarabine IV • IOV-4001
    7d
    DUET-BTC: Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    HER-2 positive • HER-2 amplification
    |
    cyclophosphamide • fludarabine IV